AG Oncon, LLC v. Ligand Pharmaceuticals, Inc.

Supreme Court of Delaware

AG Oncon, LLC v. Ligand Pharmaceuticals, Inc.

DecidedJanuary 10, 2020

Docket300, 2019

StatusPublished

This text of AG Oncon, LLC v. Ligand Pharmaceuticals, Inc. (AG Oncon, LLC v. Ligand Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

AG Oncon, LLC v. Ligand Pharmaceuticals, Inc., (Del. 2020).

Pincite

Opinion

IN THE SUPREME COURT OF THE STATE OF DELAWARE AG ONCON, LLC, AG OFCON, § LTD, AND OPTI OPPORTUNITY § MASTER FUND, § § No. 300, 2019 Plaintiffs Below, § Appellants, § Court Below—Court of Chancery § of the State of Delaware v. § § LIGAND PHARMACEUTICALS, § C.A. No. 2018-0556 INC., § § Defendant Below, § Appellee. §

Submitted: January 8, 2020 Decided: January 10, 2020

Before SEITZ, Chief Justice; VALIHURA, VAUGHN, TRAYNOR, and MONTGOMERY-REEVES, Justices, constituting the Court en Banc. ORDER

This 10th day of January, 2020, after careful consideration of the parties’ briefs

and the record on appeal, and after oral argument, we find it evident that the final

judgment of the Court of Chancery should be affirmed on the basis of and for the

reasons stated in its May 24, 2019 memorandum opinion.

NOW, THEREFORE, IT IS ORDERED that the judgment of the Court of

Chancery is AFFIRMED.

BY THE COURT:

/s/ Collins J. Seitz, Jr. Chief Justice

Free access — add to your briefcase to read the full text and ask questions with AI